EVOLUS, INC.
Pharmaceutical Preparations- 売上
- $297m
- 時価総額
- $404m
株価 $6.22 · 100株 622円
美容医療分野でしわ改善の注射剤を医師向けに提供し消費者が直接費用を支払う市場で収益を上げる
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $202m | $266m | $297m |
| 成長率 | — | 31.8% | 11.6% |
| 総利益 | $138m | $182m | $197m |
| 総利益率 | 68.1% | 68.5% | 66.3% |
| 販管費 | $165m | $198m | $221m |
| 販管費率 | 81.6% | 74.4% | 74.3% |
| 営利 | ▲$49m | ▲$34m | ▲$33m |
| 営利率 | ▲24.4% | ▲12.9% | ▲11.0% |
| 純利益 | ▲$62m | ▲$50m | ▲$52m |
| PBR | — | 73.2 | — |
| PSR | 2.0 | 1.5 | 1.4 |
| PGPR | 2.9 | 2.2 | 2.1 |
| PER | — | — | — |
| ネットキャッシュ | ▲$11m | $13m | ▲$20m |
| EV/EBITDA | — | — | — |
| Rule of 40 | — | 19% | 1% |
| セールス効率 | — | 135% | 65% |
※Rule of 40は売上成長率+営業利益率、セールス効率は売上総利益増加÷販管費増加(販管費増のときのみ)
